<div class="white-sheet">
	<div class="content-slide">

		<!-- Secondary scene 1 -->
		<div class="content secondary-scene">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-1-3">

			<div class="vertical-nav">
                <ul class="two">
                    <li class="active"></li>
                    <li></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: <br />data analysis
			</div>


			<div class="content-container" style="overflow-y: scroll;-webkit-overflow-scrolling: touch;">

				<ul>
					<li><span>To test the null hypothesis, response probability was set at ≤10%<sup>1</sup></span>
						<ul>
							<li><span>The null hypothesis would be accepted if the number of patients with a response at 12 weeks was five or less</span></li>
						</ul>
					</li>
					<li><span>Response probability for the alternative hypothesis was set at ≥30%<sup>1</sup></span></li>
					<li><span>The initial phase of the trial included 25 patients, based on testing of the null hypothesis at a significance level of 0.05 and a power of 80%<sup>1</sup></span></li>
					<li><span>Additional patients were enrolled in an extension study, to focus on duration and quality of response, the impact of eltrombopag discontinuation in robust responders and the incidence of cytogenetic abnormalities<sup>2</sup></span>
						<ul>
							<li><span>A further 18 patients were enrolled in the expanded trial to give a total of 44 patients with refractory SAA</span>
								<ul>
									<li><span>43 patients received eltrombopag treatment</span></li>
								</ul>
							</li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Olnes M <i>et al. N Engl J Med</i> 2012;367:11</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Desmond R <i>et al. Blood</i> 2014;123:1818</span></li>
			</ul>

		</div>

		</div>

		<!-- End of secondary scene 1 -->
		<!-- Secondary scene 2 -->
		<div class="content secondary-scene">

		<div class="title-bar blue"></div>

		<div class="wrapper slide-3-3-1a">

			<div class="vertical-nav">
                <ul class="two">
                    <li></li>
                    <li class="active"></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information2-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title blue two-line">
				Phase II study in refractory aplastic anaemia: <br />baseline characteristics (cohorts 1 and 2)
			</div>


			<div class="content-container" style="overflow-y: scroll;-webkit-overflow-scrolling: touch;">

				<table class="blue">
					<tr>
						<th>Characteristic<sup>1</sup></td>
						<th>Patients (N=43)</td>
					</tr>
					<tr class="odd">
						<td>Mean age, years (SD)</td>
						<td>45.5 (19.82</td>
					</tr>
					<tr>
						<td>Age group (years), n (%)<br />
							&lt;18<br />
							18–64<br />
							65–74<br />
							≥75
						</td>
						<td>
							<br />
							2 (5)<br />
							27 (63)<br />
							12 (28)<br />
							2 (5)
						</td>
					</tr>
					<tr class="odd">
						<td>Ethnicity: White/Black/Asian/Hispanic, %</td>
						<td>47/30/2/21</td>
					</tr>
					<tr>
						<td>Male, %</td>
						<td>56</td>
					</tr>
					<tr class="odd">
						<td>Median time since diagnosis, months (range)</td>
						<td>30.9 (10–190)</td>
					</tr>
					<tr>
						<td>≥1 prior course of IST, %</td>
						<td>100</td>
					</tr>
					<tr class="odd">
						<td>Transfusion required, %<br />
							RBCs<br />
							Platelets
						</td>
						<td>
							<br />
							86<br />
							91
						</td>
					</tr>
					<tr class="odd">
						<td>Abnormal karyotype, %</td>
						<td>7</td>
					</tr>
					<tr>
						<td>
							Cell type, median laboratory values (range)<br />
							Platelets, cells ×10–3/mm3<br />
							Neutrophils, cells ×10–3/mm3<br />
							Haemoglobin, g/dl<br />
							Reticulocytes, cells ×10–3/mm3

						</td>
						<td><br />
							20 (6–90)<br />
							0.58 (0.07–2.81)<br />
							8.4 (6.6–13.8)<br />
							24.3 (1.7–96.9)
						</td>
					</tr>
					<tr class="odd">
						<td>Severe cytopenias, n (%)<br />
							Neutropenia &lt;0.5 Gi/l<br />
							Thrombocytopenia &lt;20 GI/l<br />
							Anaemia &lt;10.0 g/dl
						</td>
						<td>
							<br />
							18 (42)<br />
							18 (42)<br />
							35 (81)
						</td>
					</tr>
				</table>
			</div>

		</div>


		<div class="references2-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ol>

		</div>


		<div class="information2-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: baseline characteristics (cohorts 1 and 2)</header>
				
			<ul>
				<li><span>The combination of the key endpoints of the phase II study and the baseline characteristics of the patient population were the basis of the dose-adjustment criteria used in the prescribing information for eltrombopag</span>
					<ul>
						<li><span>In multilineage responders, once platelet count is >50×109/l, haemoglobin is >10 g/dl in the absence of red blood cell (RBC) transfusions and absolute neutrophil count (ANC) is >1×109/l for more than 8 weeks, the dose of eltrombopag should be reduced by up to 50%<sup>2</sup></span></li>
						<li><span>If these counts stay stable after 8 weeks at the reduced dose, eltrombopag may be discontinued<sup>2</sup></span>
							<ul>
								<li><span>This is in agreement with the duration of transfusion independence and the main efficacy criteria specified in the phase II study<sup>1</sup></span></li>
							</ul>
						</li>
					</ul>
				</li>
				<li><span>Number of prior immunosuppressive therapies (N=43), n (%)<sup>1</sup></span>
					<ul>
						<li><span>≥1: 43 (100)</span></li>
						<li><span>≥2: 36 (84)</span></li>
						<li><span>≥3: 14 (33)</span></li>
						<li><span>≥4: 3 (7)</span></li>
					</ul>
				</li>
				<li><span>Prior IST medication, n (%)<sup>1</span>
					<ul>
						<li><span>Horse ATG-based regimen, 41 (95); rabbit ATG-based regimen, 25 (58); alemtuzumab, 15 (35); cyclophosphamide, 6 (14); other ATG (non-specified), 1 (2)</span></li>
					</ul>
				</li>
				<li><span>Current medical conditions in ≥10% of subjects, n (%)<sup>1</sup></span>
					<ul>
						<li><span>Iron overload, 20 (47); fatigue, 17 (40); hypertension, 9 (21); depression, 7 (16); anxiety, 6 (14); epistaxis, 6 (14)</span></li>
					</ul>
				</li>
			</ul>

		</div>

		</div>
		<!-- End of secondary scene 2 -->

	</div>
</div>